Journal article
Incretin-Based Therapies
The Medical clinics of North America, Vol.99(1), pp.107-129
01/2015
Handle:
https://hdl.handle.net/2376/108309
PMID: 25456646
Abstract
Incretin hormones, namely glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide, have been recognized for some time as playing a key role in glucose homeostasis, with the effects of incretin hormones believed to be responsible for up to 60% of postprandial insulin release. Two predominant therapeutic strategies have been developed to augment the incretin response: (1) GLP-1 receptor agonists resistant to degradation by the enzyme dipeptidyl peptidase 4 (DPP-4); and (2) DPP-4 inhibitors. With an expanding arsenal of incretin-based therapies available, understanding the differentiating efficacy and safety profiles for available agents is important in optimizing drug selection and patient outcomes.
Metrics
9 Record Views
Details
- Title
- Incretin-Based Therapies
- Creators
- Joshua J Neumiller - Department of Pharmacotherapy, College of Pharmacy, Washington State University, PO Box 1495, Spokane, WA 99210-1495, USA
- Publication Details
- The Medical clinics of North America, Vol.99(1), pp.107-129
- Academic Unit
- Pharmacotherapy, Department of
- Publisher
- Elsevier Inc
- Grant note
- Johnson & Johnson Amylin Novo Nordisk AstraZeneca (http://dx.doi.org/10.13039/100004325) Merck
- Identifiers
- 99900547208901842
- Language
- English
- Resource Type
- Journal article